Phase 2 Vasculitis Trial, Recruiting NCT06923072 Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Condition: Vasculitis
Back to Vasculitis

Phase 2 Vasculitis Trial, Recruiting

NCT06923072
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are willing and able to sign a consent form, or have someone legally authorized to sign on your behalf.
  • You are willing to follow all study procedures and be available for the full duration of the study.
  • You are male or female, aged 18 or older.
  • You have been diagnosed with systemic Degos disease that is affecting your nervous system, as shown by symptoms, imaging, or lab results.
  • You are able to swallow pills and are willing to take the study medication (baricitinib) as directed.
  • If you are a woman who could become pregnant, you are not currently pregnant or breastfeeding, and you agree to use highly effective birth control during the study and for 30 days after your last dose.
  • You or your legal representative are able to understand and sign a written consent form.

Who may not be able to join:

  • You have an active infection that is not responding to treatment.
  • Your red blood cell levels (hemoglobin) are too low (confirm with trial site).
  • Your platelet count (cells that help blood clot) is too low (confirm with trial site).
  • Your white blood cell levels are too low, specifically neutrophils or lymphocytes (confirm with trial site).
  • Your liver function test results are more than twice the normal upper limit.
  • Your kidneys are not working well enough, based on a specific measurement of kidney function (confirm with trial site).
  • Within the past 12 weeks, you have had a blood clot, heart attack, unstable heart disease, stroke, or severe heart failure.
  • You have had a shingles (herpes zoster) outbreak with symptoms within the past 12 weeks.
  • You have lived with someone who had active tuberculosis (TB) and did not receive proper preventive treatment for TB.
  • You have signs of active or latent (inactive) TB infection.
  • You have received a live vaccine within the past 12 weeks, or expect to need one during the study.
  • You have poor kidney function and would need a certain type of contrast dye for medical imaging (confirm with trial site).
  • You are currently breastfeeding.
  • You are currently pregnant.
  • You have a cancer that is not under control.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Cornelia D Cudrici, M.D., National Heart, Lung, and Blood Institute (NHLBI)

Phone: (301) 402-9841

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
18 February 2026
Est. completion
14 December 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with stability of existing enhancing lesions in the brain and/or spine observed in MRI; Number of participants with no new enhancing lesions in the brain and/or spine observed in MRI

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov